Key result
Warfarin reduced the risk of systemic embolism by 71% compared to placebo (OR = 0.29) and 50% compared to antiplatelet agents (OR = 0.50) without increasing major bleeding risk.
Why the study?
Does warfarin prevent systemic embolism in patients with non-valvular atrial fibrillation?
Population
Patients with non-valvular atrial fibrillation
Comparison
Warfarin vs Antiplatelet agents, placebo, or low-dose warfarin
Design
Meta-analysis
Authors
Loading...
Supports warfarin over antiplatelets to prevent embolism in non-valvular AF without excess bleeding; confirms prior randomized evidence.
Does warfarin prevent systemic embolism in patients with non-valvular atrial fibrillation?
In patients with non-valvular atrial fibrillation, warfarin significantly reduces the risk of systemic embolism compared to antiplatelet agents without increasing the risk of major bleeding.
Andersen et al. (2008) studied this question. Warfarin reduced the risk of systemic embolism by 71% compared to placebo (OR = 0.29) and 50% compared to antiplatelet agents (OR = 0.50) without increasing major bleeding risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: